Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!

PHIO Insider Trading (Phio Pharmaceuticals)

Insider Ownership Percentage: 0.52%
Insider Buying (Last 12 Months): $5,000.00
Insider Selling (Last 12 Months): $0.00

Phio Pharmaceuticals Insider Trading History Chart

Phio Pharmaceuticals Share Price & Price History

$3.09
▼ -0.2 (-6.08%)
As of 02/25/2021 01:00 AM ET
Days: 30 | 90 | 365
This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

Phio Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2020Gerrit DispersynCEOBuy2,000$2.50$5,000.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Phio Pharmaceuticals (NASDAQ:PHIO)

1.77% of Phio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Phio Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
2/25/2021Dimensional Fund Advisors LP25,177$68K0.0%N/A0.178%
2/4/2021GSA Capital Partners LLP101,401$0.27M0.0%+376.6%1.754%
12/11/2020Virtu Financial LLC35,929$77K0.0%N/A0.622%
11/6/2020GSA Capital Partners LLP21,278$46K0.0%N/A0.368%
7/16/2020Wedbush Securities Inc.33,374$73K0.0%N/A0.577%
5/15/2020Sabby Management LLC255,194$0.45M0.2%N/A8.901%
5/12/2020JPMorgan Chase & Co.21,681$38K0.0%N/A0.755%
2/14/2020UBS Group AG45,409$0.43M0.0%+43.3%6.997%
2/13/2020Renaissance Technologies LLC333,890$57K0.0%+585.9%51.447%
1/28/2020SG Americas Securities LLC792,374$0.14M0.0%+12.3%121.904%
11/4/2019SG Americas Securities LLC705,353$0.19M0.0%+16.9%2.756%
8/16/2019CVI Holdings LLC406,358$0.15M0.1%-32.8%1.701%
8/14/2019Citadel Advisors LLC85,621$33K0.0%+148.9%0.358%
6/30/2019SG Americas Securities LLC603,528$0.23M0.0%+163.8%2.526%
4/29/2019SG Americas Securities LLC228,825$0.10M0.0%+39.8%1.026%
4/12/2019Virtu Financial LLC238,544$0.11M0.0%N/A1.070%
Data available starting January 2016

See Full Table
Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $3.09
$3.00
$3.37

50 Day Range

MA: $3.24
$2.81
$4.05

52 Week Range

Now: $3.09
$1.60
$6.48

Volume

923,899 shs

Average Volume

1,566,874 shs

Market Capitalization

$43.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

Who are the company insiders with the largest holdings of Phio Pharmaceuticals?

Phio Pharmaceuticals' top insider shareholders include:
  1. Gerrit Dispersyn (CEO)

Who are the major institutional investors of Phio Pharmaceuticals?

Phio Pharmaceuticals' top institutional investors include:
  1. GSA Capital Partners LLP — 1.75%
  2. Dimensional Fund Advisors LP — 0.18%

Which institutional investors are buying Phio Pharmaceuticals stock?

During the previous quarter, PHIO stock was purchased by institutional investors including:
  1. GSA Capital Partners LLP
  2. Dimensional Fund Advisors LP
Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!